Annals of Oncology最新文献

{"title":"Maintenance treatment in sarcomas: who is it for?","authors":"A Constantinidou, R L Jones","doi":"10.1016/j.annonc.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.05.002","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Comments on the study of lung cancer detection by electronic nose analysis of exhaled breath.","authors":"Gaetano Rocco","doi":"10.1016/j.annonc.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.05.004","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study.","authors":"Juntong Liu, Yan Shi, Yufeng Yang","doi":"10.1016/j.annonc.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.05.003","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation Study of Electronic Nose Detection for Lung Cancer.","authors":"Lukasz Szarpak, Michal Pruc, Magdalena Bizon, Maciej Olszewski","doi":"10.1016/j.annonc.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.05.005","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LONG-TERM DEVELOPMENT OF 12- AND 15-YEAR-OLD OFFSPRING AFTER MATERNAL CANCER DIAGNOSIS DURING PREGNANCY: A PROSPECTIVE MULTICENTRE COHORT STUDY.","authors":"E A Huis In 't Veld, I A Van Assche, K Van Calsteren, T Salaets, M G Slieker, E Cardonick, M van Grotel, M J Halaska, C Fontana, R Fruscio, J Lemiere, M van Gerwen, E M van Dijk-Lokkart, C L Lejeune, H van Tinteren, L Mertens, V Tomek, S Posthouwer, J Voigt, M M van den Heuvel-Eibrink, L Lagae, F Amant","doi":"10.1016/j.annonc.2025.04.011","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.04.011","url":null,"abstract":"<p><strong>Background: </strong>Evidence is lacking on the long-term effects of prenatal exposure to maternal cancer and its treatment on adolescent neurocognitive, cardiac, and physical health.</p><p><strong>Methods: </strong>In a multicentre cohort study, children aged 12 and/or 15 years, prenatally exposed to maternal cancer (treatment), underwent clinical, echocardiographic, and neurocognitive evaluations. Standardized assessments were used, and associations between neurocognitive outcomes and covariates were examined using one-way and multivariable ANOVA. Further analyses examined the need for extra support and the impact of chemotherapy exposure on puberty onset.</p><p><strong>Findings: </strong>Of 166 children, 122 children were exposed to chemotherapy, 17 to surgery alone, 14 to radiotherapy, one to trastuzumab, one to rituximab, and 21 to no treatment. Cardiac function was within normal ranges, with a median ejection fraction of 56.7% (z-score: -1.6) and two cases showing mild systolic dysfunction (EF <50%). Neurocognitive outcomes, including intelligence, memory, and attention, were also within normal limits. However, 9 children had lower verbal memory scores linked to chemotherapy exposure (β = -0.52, p = .044). Visuospatial memory was negatively correlated with maternal death (β = -0.55, p = .019), and attention was influenced by prematurity (β = 0.034 per gestational week, p = .020) and male sex (β = -0.17, p = .024). Extra support was needed in 21 children, primarily associated with lower intelligence, attention, and executive function scores, as well as prematurity. Pubertal development was within standard ranges, with no significant associations found between chemotherapy exposure and puberty onset.</p><p><strong>Interpretation: </strong>Overall, no significant disruptions were found in the neurocognitive, cardiac, or physical development of adolescents prenatally exposed to maternal cancer and its treatment. Observed vulnerabilities, such as lower verbal memory and attention scores, were primarily linked to prematurity and maternal death rather than maternal cancer or its treatment. Ongoing monitoring is recommended to understand long-term outcomes into adulthood.</p><p><strong>Funding: </strong>Kom Op Tegen Kanker, KWF Kankerbestrijding, Stichting Tegen Kanker, Fonds Wetenschappelijk Onderzoek, Cooperatio Program.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives.","authors":"A Marra, S Morganti, F Pareja, G Campanella, F Bibeau, T Fuchs, M Loda, A Parwani, A Scarpa, J S Reis-Filho, G Curigliano, C Marchiò, J N Kather","doi":"10.1016/j.annonc.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.03.006","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) is rapidly transforming the fields of pathology and oncology, offering novel opportunities for advancing diagnosis, prognosis, and treatment of cancer.</p><p><strong>Methods: </strong>Through a systematic review-based approach, the representatives from the European Society for Medical Oncology (ESMO) Precision Oncology Working Group (POWG) and international experts identified studies in pathology and oncology that applied AI-based algorithms for tumour diagnosis, molecular biomarker detection, and cancer prognosis assessment. These findings were synthesised to provide a comprehensive overview of current AI applications and future directions in cancer pathology.</p><p><strong>Results: </strong>The integration of AI tools in digital pathology is markedly improving the accuracy and efficiency of image analysis, allowing for automated tumour detection and classification, identification of prognostic molecular biomarkers, and prediction of treatment response and patient outcomes. Several barriers for the adoption of AI in clinical workflows, such as data availability, explainability, and regulatory considerations, still persist. There are currently no prognostic or predictive AI-based biomarkers supported by level IA or IB evidence. The ongoing advancements in AI algorithms, particularly foundation models, generalist models and transformer-based deep learning, offer immense promise for the future of cancer research and care. AI is also facilitating the integration of multi-omics data, leading to more precise patient stratification and personalised treatment strategies.</p><p><strong>Conclusions: </strong>The application of AI in pathology is poised to not only enhance the accuracy and efficiency of cancer diagnosis and prognosis but also facilitate the development of personalised treatment strategies. Although barriers to implementation remain, ongoing research and development in this field coupled with addressing ethical and regulatory considerations will likely lead to a future where AI plays an integral role in cancer management and precision medicine. The continued evolution and adoption of AI in pathology and oncology are anticipated to reshape the landscape of cancer care, heralding a new era of precision medicine and improved patient outcomes.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population.","authors":"M P Akamandisa, N J Boddicker, S Yadav, C Hu, S N Hart, C Ambrosone, H Anton-Culver, P L Auer, C Bodelon, E S Burnside, F Chen, A H Eliassen, D E Goldgar, C Haiman, J M Hodge, H Huang, E M John, R Karam, J V Lacey, S Lindstroem, E Martinez, J Na, S L Neuhausen, K M O'Brien, J E Olson, T Pal, J R Palmer, A V Patel, T Pesaran, E C Polley, M E Richardson, K Ruddy, D P Sandler, L R Teras, A Trentham-Dietz, C M Vachon, C Weinberg, S J Winham, S Yao, G Zirpoli, P Kraft, J N Weitzel, S M Domchek, F J Couch, K L Nathanson","doi":"10.1016/j.annonc.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.04.010","url":null,"abstract":"<p><strong>Background: </strong>Pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk. However, it is unknown whether this risk differs by PV type or location in carriers ascertained from the general population.</p><p><strong>Patients and methods: </strong>To evaluate breast cancer risks associated with PV type and location in ATM, BRCA1, BRCA2, CHEK2, and PALB2, we performed age adjusted case-control association analysis in 32,247 women with and 32,544 age-matched women without breast cancer from the CARRIERS Consortium. PVs were grouped by type and location within genes and assessed for risks of breast cancer (odds ratios (OR), 95% confidence intervals (CI), and P-values) using logistic regression.</p><p><strong>Results: </strong>Compared to women carrying BRCA2 exon 11 protein truncating variants (PTVs) in the CARRIERS population-based study, women with BRCA2 ex1-10 PTVs (OR=13.5, 95%CI 6.0-38.7, P<0.001) and ex13-27 PTVs (OR=9.0, 95%CI 4.9-18.5, P<0.001) had higher breast cancer risks, lower rates of ER-negative breast cancer (ex13-27 OR=0.5, 95%CI 0.2-0.9, P=0.035; ex1-10 OR=0.5, 95%CI 0.1-1.0, P=0.065), and earlier age at breast cancer diagnosis (ex13-27 5.5 years, P<0.001; ex1-10 2.4 years, P=0.169). These associations with ER-negative breast cancer and age replicated in a high-risk clinical cohort from Ambry Genetics and the population-based UK Biobank cohort. No differences in risk by gene region were observed for PTVs in other predisposition genes.</p><p><strong>Conclusion: </strong>Population-based and clinical high-risk cohorts establish that PTVs in exon 11 of BRCA2 are associated with reduced breast cancer risk, later age at diagnosis, and greater risk of ER-negative disease. These differential risks may improve individualized risk prediction and clinical management for women carrying BRCA2 PTVs.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial to introduce article \"Enrichment of CD7+CXCR3+ CAR T cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma\".","authors":"J-M Michot, C Bigenwald","doi":"10.1016/j.annonc.2025.04.008","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.04.008","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study.","authors":"J Zhang, R Liu, S Wang, Z Feng, H Yang, S Gao, X Li, X Yao, J Chen, Z Gong, Y Li, X Li, S Wang, C Hu, J Liu, M Zhang, F Yuan, B Shi, H Lou, P Zhao, F Qiu, H Guo, B Hu, D Xu, H Huang, X Zhang, M Feng, X Wang, G Li, D Liu, X Chen, P Wang","doi":"10.1016/j.annonc.2025.04.009","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.04.009","url":null,"abstract":"<p><strong>Backgroud: </strong>A first-in-human study was performed to assess the safety and preliminary antitumor activity of 9MW2821, a next-generation monoclonal antibody-drug conjugate (ADC) that delivers monomethylauristatin E (MMAE) to cells expressing Nectin-4, in patients with advanced solid tumors.</p><p><strong>Patients and methods: </strong>This is a first-in-human, open label, multicenter study included dose escalation, dose expansion and cohort expansion periods. Patients with advanced solid tumors who failed ≥1 line of systemic therapy were recruited to receive 9MW2821 by intravenous (IV) infusion at doses of 0.33-1.5mg/kg on days 1,8 and 15 of each 28-day cycle. Primary objective were assessment of safety and preliminary efficacy. (NCT05216965, CTR20220106) RESULTS: Between June 11, 2022, and Apr 3, 2024, 274 patients were enrolled, including 51 with urothelial cancer, 62 with cervical cancer, 49 with esophageal cancer, 20 with triple negative breast cancer and 92 with other solid tumors. In dose escalation phase, one dose limiting toxicity was observed in 1.5mg/kg group, which was grade 4 neutropenia lasted more than 5 days. Maximum tolerated dose of 9MW2821 was not reached. However, the recommended phase Ⅱ dose was identified as 1.25mg/kg based on balance of safety and efficacy. The most common ≥Grade 3 treatment related adverse events were neutrophil count decreased, white blood cell (WBC) count decreased, anemia, gamma-glutamyl transferase (GGT) increased rash and peripheral sensory neuropathy in 1.25mg/kg group. Among 226 patients evaluable for efficacy, objective response rates were 54.1%, 32.1%, 14.0% and 50% in urothelial cancer, cervical cancer, esophageal cancer and triple negative breast cancer, respectively.</p><p><strong>Conclusion: </strong>The results suggest that 9MW2821 was tolerable and clinically significant in efficacy in various types of solid tumors besides urothelial cancer. Several pivotal trials are currently in progress. (NCT06196736, NCT06592326, NCT06692166).</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.","authors":"M-O Grimm, J Bedke, J Nyarangi-Dix, W Khoder, S Foller, H-J Sommerfeld, M Giessing, M Heck, W Meißner, A Slee, K Leucht, F von Rundstedt, G Theil, S Buse, S Siemer, P Albers, C Gratzke, M Hohenfellner, A Stenzl","doi":"10.1016/j.annonc.2025.04.005","DOIUrl":"10.1016/j.annonc.2025.04.005","url":null,"abstract":"<p><strong>Background: </strong>The prospective, randomised, open-label, multicentre OpeRa trial (NCT03849820) aimed to determine whether robotic-assisted partial nephrectomy (RAPN) is superior to open partial nephrectomy (OPN) in reducing 30-day post-operative complications during the treatment of intermediate/high-complexity renal tumours.</p><p><strong>Patients and methods: </strong>Eligible patients aged ≥18 years had a renal tumour suitable for OPN or RAPN, a RENAL score ≥7, and an estimated glomerular filtration rate ≥50 ml/min/1.73 m². Patients were randomised from 15 March 2019 to 23 November 2021 in 12 German hospitals and assigned (1 : 1) to undergo RAPN or OPN. Primary endpoint was the 30-day post-operative complication rate [Clavien-Dindo (CD) I-V] in the modified intention-to-treat population. We aimed to recruit 606 patients to detect ≥10% reduction in the primary endpoint for RAPN versus OPN.</p><p><strong>Results: </strong>A total of 240 patients were randomised to RAPN (n = 123) or OPN (n = 117). Enrolment was stopped prematurely due to slow recruitment. After patient withdrawal post-randomisation, 117 patients underwent RAPN and 90 OPN. The primary endpoint was assessable in 112 and 89 patients, respectively. The 30-day complication rate did not differ between groups: RAPN 41/112 (37%) versus OPN 41/89 (46%) (one-sided: P = 0.088). The difference of -9.5% (95% confidence interval -23.1% to 4.2%) numerically favoured RAPN. The most frequent high-grade complications (CD III-IV) to post-operative day 30 (POD30) were urine leakage [RAPN 4/112 (4%) versus OPN 2/89 (2%)] and post-operative bleeding [2/117 (2%) versus 1/89 (1%)]. Compared with OPN, RAPN patients had longer operative and warm ischaemia times, shorter hospital stay, and reported better recovery, less opioid use, less pain, and improved quality of life (QoL) up to POD30.</p><p><strong>Conclusions: </strong>There was no statistically significant difference in the 30-day complication rate between RAPN and OPN in this underpowered trial. Few high-grade complications occurred over the whole cohort with intermediate/high-complexity tumours. Despite less intense pain management, patients undergoing RAPN reported less pain and better QoL up to POD30.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}